OR WAIT null SECS
November 18, 2020
The expansion will be designed to meet the growing demand for small molecule drug substance development and manufacturing.
November 16, 2020
The new facility, which is expected to be operational by mid-2026, will utilize cell-based technology to produce influenza vaccines for influenza pandemics and seasonal vaccination programs, both in Australia and globally.
The companies will work together on research activities through to the selection of a preclinical candidate, after which Roche will handle further development and global commercialization.
The 110,000 ft2 site, which is set to be operational by the second half of 2021, will feature new technology including 2000-L scale bioreactors and additional fill-finish capabilities.
November 12, 2020
Apeiron Biologics has selected Domainex to advance the development of inhibitors for the E3 ubiquitin ligase Cbl-b.
AstraZeneca has received approval for Calquence (acalabrutinib) to be used as a treatment of chronic lymphocytic leukemia (CLL) in adults within the European Union (EU).
PhoreMost and Oxford Biomedica have entered into a discovery collaboration for the development of next-generation chimeric antigen receptor T-cell therapies.
Vifor Pharma and Angion Biomedica have signed a license agreement that will see the commercialization of late-stage product, ANG-3777.
Optibrium has entered into a cheminformatics collaboration with MSD (known as Merck & Co. in the United States).
November 11, 2020
Construction on the workshop is currently underway with plans for it to be fully operational by the end of 2021.